Literature DB >> 20144908

Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes.

Stefan Fruehauf1, Guido Tricot.   

Abstract

Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are considered the standard of care for many malignancies, including lymphoma, myeloma, and some leukemias. In many cases, mobilized peripheral blood has become the preferred source of hematopoietic stem cells. The efficacy of different mobilization regimens and transplantation outcomes based on cell doses has been well studied; however, the characteristics of the stem cell graft may be of equal importance with respect to patient outcomes following autologous or allogeneic HSCT. This review summarizes available preclinical and clinical data for bone marrow and mobilized peripheral blood HSCT characteristics, defined as the cell types found in the graft as well as their gene expression profiles. It also explores how graft characteristics can affect bone marrow homing, engraftment, immune reconstitution, and other posttransplantation outcomes in both the allogeneic and autologous HSCT settings.
Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20144908     DOI: 10.1016/j.bbmt.2010.02.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

Review 1.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

2.  Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.

Authors:  Liuyan Jiang; Sunny Malik; Mark Litzow; Dennis Gastineau; Ivana Micallef; Vivek Roy; Lawrence Solberg; Abba C Zubair
Journal:  Transfusion       Date:  2011-08-09       Impact factor: 3.157

Review 3.  Current clinical indications for plerixafor.

Authors:  Stefan Fruehauf
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

Review 4.  The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.

Authors:  Leah A Marquez-Curtis; A Robert Turner; Santhi Sridharan; Mariusz Z Ratajczak; Anna Janowska-Wieczorek
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

5.  Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.

Authors:  Andrea M Patterson; Shuhong Zhang; Liqiong Liu; Hongge Li; Pratibha Singh; Yunlong Liu; Sherif S Farag; Louis M Pelus
Journal:  Stem Cell Rev Rep       Date:  2021-09-12       Impact factor: 5.739

6.  Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.

Authors:  Barbara Skopec; Matevz Skerget; Darja Zontar; Vesna Zadnik; Samo Zver
Journal:  Wien Klin Wochenschr       Date:  2017-04-24       Impact factor: 1.704

Review 7.  Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?

Authors:  J J Auletta; S M Devine; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

8.  The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study.

Authors:  Georgine E de Greef; Eric Braakman; Bronno van der Holt; Jeroen J W M Janssen; Eefke Petersen; Vladimir Vucinic; Nicole Thuss; Meriam Grootes; Jan J Cornelissen
Journal:  Transfusion       Date:  2018-12-11       Impact factor: 3.157

9.  New strategies for stem cell mobilization.

Authors:  Roberto M Lemoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-03       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.